Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Short Interest Update

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Get Free Report) was the recipient of a significant increase in short interest during the month of April. As of April 15th, there was short interest totalling 4,880,000 shares, an increase of 21.4% from the March 31st total of 4,020,000 shares. Based on an average daily volume of 663,100 shares, the short-interest ratio is presently 7.4 days. Currently, 9.0% of the company's shares are short sold.

Insider Buying and Selling

In related news, CEO Mihael Hristos Polymeropoulos acquired 10,000 shares of the firm's stock in a transaction dated Friday, February 28th. The shares were purchased at an average cost of $4.76 per share, for a total transaction of $47,600.00. Following the acquisition, the chief executive officer now owns 2,361,730 shares in the company, valued at $11,241,834.80. The trade was a 0.43 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Over the last ninety days, insiders bought 32,000 shares of company stock worth $151,180. Insiders own 8.90% of the company's stock.

Institutional Trading of Vanda Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the company. Quantinno Capital Management LP acquired a new stake in shares of Vanda Pharmaceuticals in the 4th quarter valued at $48,000. Linden Thomas Advisory Services LLC purchased a new position in Vanda Pharmaceuticals in the first quarter valued at $49,000. XTX Topco Ltd purchased a new position in Vanda Pharmaceuticals in the fourth quarter valued at $69,000. Zacks Investment Management acquired a new stake in Vanda Pharmaceuticals in the fourth quarter valued at $74,000. Finally, ProShare Advisors LLC lifted its holdings in Vanda Pharmaceuticals by 32.4% during the 4th quarter. ProShare Advisors LLC now owns 18,815 shares of the biopharmaceutical company's stock worth $90,000 after buying an additional 4,599 shares during the last quarter. Institutional investors and hedge funds own 88.14% of the company's stock.

Analysts Set New Price Targets

Several research analysts have recently commented on VNDA shares. StockNews.com started coverage on Vanda Pharmaceuticals in a research report on Wednesday, February 5th. They set a "hold" rating for the company. HC Wainwright restated a "buy" rating and set a $20.00 target price on shares of Vanda Pharmaceuticals in a report on Tuesday, April 1st.

Vanda Pharmaceuticals Stock Performance

Shares of NASDAQ:VNDA traded down $0.22 during trading on Tuesday, hitting $4.37. The company's stock had a trading volume of 504,484 shares, compared to its average volume of 755,491. The company has a market capitalization of $257.54 million, a PE ratio of -13.66 and a beta of 0.69. Vanda Pharmaceuticals has a fifty-two week low of $3.85 and a fifty-two week high of $6.75. The business has a 50 day moving average price of $4.56 and a two-hundred day moving average price of $4.67.

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last issued its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.06. The company had revenue of $53.19 million for the quarter, compared to the consensus estimate of $51.00 million. Vanda Pharmaceuticals had a negative return on equity of 3.49% and a negative net margin of 9.51%. As a group, equities analysts expect that Vanda Pharmaceuticals will post -1.12 earnings per share for the current fiscal year.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.